Alky nitrates, in vivo, are metabolized to yield nitric oxide, and thiol groups are considered necessary cofactors. This statement is based on studies that underline how these species potentiate hemodynamic responsiveness to nitrates in patients with ischemic heart disease. However, the role of thiols might be mediated by the formation of corresponding S-nitrosothiols, and a redox process is responsible for the nitrates' degradation: an enzyme, probably the cytochrome P450, is involved in vivo. Here, we report evidence that, in vitro, no reaction between thiols and alkyl nitrates takes place, but that stronger reducing agents, such as iron (II) derivatives, are necessary: alkoxy radicals and the nitrite anion are the reaction intermediates. The latter, in slightly acidic conditions, for instance mimicking ischemic conditions, is shown to nitrosilate thiols to the corresponding Snitrosothiols: the real NO suppliers. Therefore, the direct release of NO from nitrates is excluded. Finally, the in vivo role of thiols on depletion and tolerance is also accounted for.
process, but indirectly led to hypothesize, in vivo, the predominance of the enzyme path:
i.e., an Electron Transfer process between a reductant, the enzyme, and an oxidant, the nitrate.
In particular, the cytocrome P450, the enzyme most commonly involved in drugs metabolism, 1 is characterized by a heme group able to carry out electron transport by interconversion between Fe 2+ (reduced) and Fe 3+ (oxidized) states, 2 and therefore able to induce the reductive process. In fact, this enzyme, localized in the human heart and vessels, seems the most accredited, and its involvement in the biotransformation of organic nitrates, via a so-called two-electron mechanism, leading directly to the formation of NO, has been suggested. [3] [4] [5] [6] However, this hypothesis contrasts with other reports 7-9 that highlight the intermediacy of S-nitrosothiols in NO release. Nevertheless, in principle, also via this two-electron degradative nitrate mechanism the formation of S-nitrosothiols could be accounted for, and that through the nitrosilation of the corresponding thiols. The latter process could be performed by the nitrous anhydride (N 2 O 3 ), 10 possibly formed via oxidation of NO, but it has been shown to be irrelevant in vivo because negligibly slow. 11,12 Scheme 1.
In contrast, a mono-electron process, leading to alkoxy radicals and the nitrite anion, could more readily account for the formation of S-nitrosothiols. 8 In fact, the nitrite anion, via its acid equilibrium, leads directly to the formation of nitrosilating species.
Scheme 1.
To support this hypothesis it was necessary to prove if the reduction of nitrates can really be induced by iron (II) derivatives and, to this end, nitrates such as the 5-phenyl-4-penten-1-nitrate and the 5-nitrate-1-penten should give clear evidence. In fact, the hypothesized alkoxy intermediates, besides forming the parent alcohols, can undergo rearrangements that lead to compounds whose formation is definitely a proof of a radical mechanism. Experiments conducted with these nitrates and anhydrous FeCl 2 , in anhydrous solvents, led to the detection of derivatives such as 1-5, Scheme 2.
The detection of these compounds is an unquestionable result in favor of a radical mechanism and of the role of iron (II) as a mono-electron transfer agent. Among the reaction products the corresponding di-sulphide and the nitrite anion were also evidenced. In particular, as reported in a previous paper, 12 the nitrite anion has been shown to be able to perform the nitrosilation of GSH, in a buffer solution, starting from pH 6.86, which is a value consistent with ischemic conditions. Thus, this same nitrosilating process, here conducted in vitro, could be hypothesized to occur also in vivo, and the S-nitrosothiols, via a homolytic and/or a redox mechanism, act as NO releasers.
14 Thus, the NO supplementation in vivo, starting from organic nitrates, goes through nitrosilated species formed via the nitrite anion.
One of the most troublesome aspects of organic nitrate ester therapy is the fact that patients can become refractory to their effects, i.e., a repeated and prolonged administration results in the development of tolerance, characterized by a decrease in NO production, together with a decrease in tissue thiols level. As confirmed by the renewed responsiveness to nitrate therapy when the thiol groups are restored.
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In particular, it has been hypothesized that the tolerance is affected by enzymeactivity, 3 i.e., it increases with enzyme degradation 16 The positive effect of added thiols on nitrates hemodynamic is well known, but their action seems confined to the extracellular compartment. 23 In fact, through experiments with both GSH and N-acetyl cysteine, the possibility of enhancing the glycerol trinitrate degradation in whole blood, but not in red blood cells, had been reported; 24 i.e., showing an accelerating effect apparently mediated in the plasma fraction of whole blood. Thus, thiols supplementation is more likely related to a pronounced extracellular increase of these species, rather than intracellular. (Plasma) In particular, the extracellular hypertensive action seems related mainly to the presence of GSH that is synthesized intracellularly (mM concentration), starting from cysteine and, in normal conditions, continuously and irreversibly transferred out of the cell. Thus, the cysteine, definitely the main active intracellular thiol, 25,26 due to its manifold roles, i.e., reducing agent (in comparison to the enzyme), supplier of active S-nitroso cysteine and GSH producer, will diminish over time: this can accounts for depletion.
To explain the action of added thiols, because no direct interaction between nitrates and thiols can take place, in the extracellular compartment it is the presence of components such as ascorbate, urate and bilirubin, which can act as antioxidants, responsible for the degradative reduction of nitrates to nitrite. Only then will the supplemented thiols, under the indirect action of the nitrite anion be transformed into the corresponding S-nitrosothiols: 7 these will serve as tolerance-reversing mechanism.
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The degradative NO release from alkyl nitrates takes its start from the Electron
Transfer process between the nitrate, the oxidant, and an iron (II) derivative, most probably the reducing enzyme P450, in vivo. This mechanism is supported by experiments that lead to the detection of products unquestionably supporting a radical mechanism, i.e., which can be accounted for only via an Electron Transfer process. The nitrate degradative process, besides alkoxy radicals, leads to the formation of the nitrite anion, in principle an inactive NO-derivative, but in slightly acidic conditions is able to induce the nitrosilation of thiols to the corresponding S-nitrothiols: the real NO suppliers. Furthermore, because intracellular thiols, in particular cysteine and GSH, are involved in the fundamental processes inside the cell, their concentration will diminish over time: this accounts for both depletion and for the less efficiency in the reestablishment the enzyme reducing capability, tolerance. Gluthathione, cysteine, benzylthiol, ferrous and ferric chloride are commercial products; the latter two were carefully kept anhydrous. All solvents, acetonitrile, methanol and methylene chloride, were carefully kept anhydrous.
Methods

Reagents
Nitrates degradative reactions. All the reactions were conducted in anhydrous solvents and under nitrogen atmosphere, at thermostated temperature (ranging between 37 and 60 °C). Bromotrichloromethane, or N-Bromosuccinimide, and SO 2 Cl 2 were used as spin trap for carbon centered radicals. After the workup, products were identified using standard techniques (GC-MS), and compared with data reported in the literature.
The formation of S-nitrosothiols was shown conducting experiments with two solutions containing respectively the nitrate and the iron (II) derivative, which were reacted directly in a flat cell inside the spectrometer by a mixing flow system. The characteristic S-NO absorption at 540 nm was detectable. 
Scheme legends
